POTOMAC, MD / ACCESS Newswire / September 29, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the addition of a new clinical trial site to its ongoing Phase 2 study evaluating IGC-AD1, an investigational drug candidate for treating agitation in Alzheimer's disease. The new site, Ichor Research, located in Syracuse, New York, is led by Principal Investigator Dr. Karl F. ...

Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and ...

Key Takeaways Eli Lilly won EU marketing approval for Kisunla to treat early symptomatic Alzheimer's disease.The approval was backed by TRAILBLAZER studies showing Kisunla slowed cognitive and functional decline.The FDA also clears Inluriyo for ER , HER2- breast cancer with ESR1 mutations after prior endocrine therapy.Eli Lilly and Company (LLY) announced that the European Commission (EC) has granted marketing authorization to Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (A ...

Accessibility StatementSkip Navigation Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the treatment of early symptomatic Al ...

Biogen (NasdaqGS:BIIB) FY Conference September 24, 2025 11:20 AM ET Company ParticipantsPriya Singhal - EVP & Head - DevelopmentConference Call ParticipantsWilliam Pickering - Senior AnalystWilliam PickeringIn many ways, I think that Biogen needs no introduction. It's a long, well-known company in our industry. Maybe you could take a few moments to speak to the journey that you've been on to create a new Biogen and how your approach to R&D is evolving.Priya SinghalYes, we've been very excited to create the ...

POTOMAC, MD / ACCESS Newswire / September 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced preclinical findings on TGR-63, the Company's investigational small-molecule candidate for Alzheimer's disease. The data demonstrate that TGR-63 extends its therapeutic potential beyond previously reported effects on beta-amyloid (A) pathology by also inhibiting tau protein aggregation, another key hallmark of Alzheimer's. ...

TOKYO and CAMBRIDGE, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild de ...

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 23, 2025 8:30 AM EDT | Source: InMed PharmaceuticalsAdvances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathologyFurther develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular DegenerationCash of $11.1M to support pharmaceutical developments into the fourth quarter of calendar year 2026Vancouver, Brit ...

POTOMAC, MD / ACCESS Newswire / September 22, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has reached a key enrollment milestone of 50% for its ongoing Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation in Alzheimer's disease. This milestone marks a significant step in advancing IGC-AD1, the Company's proprietary formulation that combines low concentrations of delta-9 tetrahy ...

19 September 2025 | 6:01AM BST | NOVOb.CO | 12m Price Target: Dkr392.00 | Price: Dkr392.50 | Downside: 0.1% | | --- | --- | --- | --- | | NVO | 12m Price Target: $61.00 | Price: $61.85 | Downside: 1.4% | In the week to date of EASD, Novo shares have risen by c.13% vs. SXDP c.-1% which, on the one hand, is generous in our view, as while management seemed incrementally more positive on the pipeline and obesity portfolio at the R&D event, the data presented by Novo at the conference were largely incremental, i ...